insitro

Insitro, Inc. operates a machine-learning-based platform focused on drug discovery and development, particularly for the treatment of nonalcoholic steatohepatitis (NASH). Established in 2018 and located in South San Francisco, California, the company integrates advanced life sciences, engineering, and data science to address critical challenges in pharmaceutical research and development. By leveraging high-throughput biology and state-of-the-art bioengineering technologies, Insitro generates extensive functional genomic datasets and aligns them with patient data through innovative machine learning techniques. This approach allows the company to create predictive models that enhance target selection, streamline the design of therapeutics, and inform clinical strategies, ultimately aiming to transform how drugs are discovered and delivered to patients.